Overview

Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
Treatment with CS-1008 in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil [5-FU]) in subjects with metastatic colorectal cancer (CRC) who have failed first-line treatment that was not irinotecan-based.
Phase:
Phase 1
Details
Lead Sponsor:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Fluorouracil
Irinotecan
Leucovorin